Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials

已完结 10 由 Simone 发布于 2025/12/5 17:01:33

DOI:10.1016/s2468-1253(25)00267-5
作者：Jian Li, Zhenghang Wang, Jing Huang, Yi Ba, Baoshan Cao, Suxia Luo, Wenhua Li, Chunmei Bai, Zhengbo Song, Jianping Xiong, Liangjun Zhu, Guangyu An, Yanqiao Zhang, Zhihua Li, Yongsheng Li, Yanhong Gu,
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundKRASG12C mutations are present in around 4% of patients with colorectal cancer and are associated with lower treatment response rates and overall survival. EGFR signalling has been

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:NatureReduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells